Tag: headache

1. For patients with medication overuse headache, withdrawal and preventive medication was more effective at reducing headache than other strategy alone. Evidence Rating: 1 (Excellent) Medication overuse headache (MOH) affects more than 60 million people globally and is considerably disabling. Although current guidelines recommend withdrawal of medication and preventive medication usage,...
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study 1. In patients with confirmed SARS-CoV-2 infection within 7 days before or 30 days after surgery, significant mortality was observed, and perioperative pulmonary complications occurred in more than half the patients. Evidence Rating: 2 (Good) Current...
1. In this multicenter study involving adult patients in the United States with a history of migraine, ubrogepant was shown to be more effective than placebo in providing freedom from pain and alleviating the most bothersome symptom within two hours. 2. Doubling the dosage of ubrogepant resulted in limited efficacy...
1. In this multicenter study involving adult patients in the United States with a history of migraine, ubrogepant was shown to be more effective than placebo in providing freedom from pain and alleviating the most bothersome symptom within two hours. 2. Doubling the dosage of ubrogepant resulted in limited efficacy...
1. Patients with episode cluster headaches randomized to receive galcanezumab experienced a greater decline in frequency of headaches 1 to 3 weeks after treatment compared to placebo treated patients. 2. Injection-site pain occurred in patients receiving galcanezumab, though no notable differences in overall adverse events was seen between treatment and...
1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo. 2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo. Evidence Rating Level: 1 (Excellent)...
1. Patients with episode cluster headaches randomized to receive galcanezumab experienced a greater decline in frequency of headaches 1 to 3 weeks after treatment compared to placebo treated patients. 2. Injection-site pain occurred in patients receiving galcanezumab, though no notable differences in overall adverse events was seen between treatment and...
1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo. 2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo. Evidence Rating Level: 1 (Excellent)...